TPI Composites files for Chapter 11 bankruptcy, plans delisting from Nasdaq
Paul A. Mahon, Executive Vice President and General Counsel of United Therapeutics Corp (NASDAQ:UTHR), a $13.14 billion market cap company with excellent financial health and a perfect Piotroski Score of 9, recently sold a significant portion of his holdings in the company. On April 3, Mahon exercised stock options to acquire 11,000 shares of common stock at $117.76 per share, totaling approximately $1.3 million.
Subsequently, Mahon sold 10,000 shares over several transactions at prices ranging from $298.00 to $308.08 per share. The total value of these sales amounted to approximately $3.37 million. Following these transactions, Mahon holds 36,781 shares of United Therapeutics. These transactions were conducted under a pre-arranged 10b5-1 trading plan.
In other recent news, United Therapeutics Corporation reported its fourth-quarter 2024 earnings, which fell short of analysts’ expectations. The company posted an earnings per share (EPS) of $6.19, below the anticipated $6.68, and revenue of $735.9 million, slightly under the forecasted $739.92 million. Despite these misses, United Therapeutics achieved record annual revenue growth for the third consecutive year, with a 24% increase over 2023. Key products such as Tyvaso and Orenitram showed significant revenue growth, with increases of 19% and 28%, respectively.
Goldman Sachs analyst Chris Shibutani adjusted the price target for United Therapeutics to $293 from $302, maintaining a Neutral rating. This adjustment was influenced by a modest reduction in Tyvaso forecasts and increased research and development spending. The analyst noted that Tyvaso, a key growth product, underperformed expectations, which could be a concern with the anticipated market entry of a competitor product by 2025.
The company continues to advance its pipeline, with significant clinical trial progress expected to contribute to future growth. United Therapeutics did not provide financial guidance, consistent with its standard practice, and while further share repurchases are possible, no new plans were announced. The company’s first UKidney transplant, expected around mid-2025, is anticipated to attract media attention and could help define the commercial opportunity scope.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.